Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the progression-free survival (PFS) data for patients with metastatic non-squamous non-small cell lung cancer treated with pembrolizumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:09.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    48%
    Check dated 2024-05-22T21:36:45.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:57:03.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.